Oklahoma City’s Nikola Topic, 20, Diagnosed with Cancer
 
                                Nikola Topic, a guard for the Oklahoma City Thunder, has been diagnosed with testicular cancer at just 20 years old. Following his diagnosis, he has started chemotherapy treatment.
Nikola Topic’s Medical Journey
On October 6, 2023, Topic underwent a biopsy at the renowned MD Anderson Cancer Center in Houston. The Oklahoma City Thunder’s general manager, Sam Presti, shared that doctors are optimistic about Topic’s long-term prognosis. The results confirmed that he is battling testicular cancer.
- Date of Biopsy: October 6, 2023
- Location: MD Anderson Cancer Center, Houston
- Diagnosis: Testicular cancer
- Age: 20 years old
Focus on Health and Recovery
Presti emphasized that Topic is dedicated to his recovery. The team has fully supported him. “Our expectations are for him to focus on this health journey,” he stated. There is no specific timeline for his return to basketball.
Despite his health challenges, Topic has maintained an active routine. He continues to train and work out throughout his treatment, showcasing his resilience.
Background on Nikola Topic
Topic, who was the 12th overall pick in the 2024 NBA Draft, has faced significant challenges early in his career. He suffered a serious knee injury, preventing him from playing during the 2024-25 season when the Thunder secured the NBA Championship.
The team and fans remain hopeful for Topic’s recovery and return to the sport he loves. As he navigates this difficult time, the support from the Oklahoma City community continues to grow.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
                                                                                                                                                     
                                                                                                                                                     
                                                                                                                                                     
                                                                                                                                                     
                                                                                                                                                     
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                            